Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Including medical news, pharmaceutical industry news, new drug approvals, applications and clinical trial results.
Daily MedNews
Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
Vioxx Study Was 'Stealth' Marketing: Report
Stealth marketing was the main goal of a 1999 Vioxx study touted by Merck & Co. as proof that the...
-- Here are the latest clinical trials, courtesy of CenterWatch:
Obesity
If you are aged 18 to 60, moderately overweight with a body mass index (BMI) between 30 and 40, weigh between 187 and 297 pounds, are in general good health, have had no...
TUESDAY, Aug. 19 -- Zoledronic acid prevents bone loss in breast cancer patients undergoing endocrine therapy and improves bone mineral density after treatment, according to an Austrian study.
Adjuvant endocrine therapy is widely used in patients...
TUESDAY, Aug. 19 -- High levels of arsenic in urine may be linked with a higher risk of developing type 2 diabetes, researchers report.
The findings, published in the Aug. 20 issue of the Journal of the American Medical Association, are the first to...
TUESDAY, Aug. 19 -- A mathematical model to find blood biomarkers that can help doctors estimate the size of cancer tumors has been developed by researchers at Stanford University.
The team says its work may help guide development of new tests to...
Pharma Industry News
NEW YORK, August 19, 2008 – Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of erectile dysfunction drug tadalafil (Cialis®) to relieve associated lower urinary tract symptoms (LUTS), according to a new...
ASMANEX is the first and only once-daily inhaled corticosteroid inhaler approved for children as young as age 4
KENILWORTH, N.J., August 19, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that ASMANEX(R) TWISTHALER(R) 110...
Information for Healthcare Professionals
Exenatide (marketed as Byetta)
Update 8/18/2008: Since issuing Information for Healthcare Professionals in October 2007, FDA has received reports of 6 cases of hemorrhagic or necrotizing...
TOKYO, Aug. 18, 2008--SymBio Pharmaceuticals Limited. (Headquarters: Tokyo, President and CEO: Fuminori Yoshida, “SymBio”) and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today...
TORONTO, Aug. 11, 2008-Patients who use proton pump inhibitors for 7 or more years to treat reflux, peptic ulcers and other conditions are at greater risk of osteoporosis-related fractures, according to this large observational study,...
New Drug Approvals
WASHINGTON, August 15, 2008 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Xenazine (tetrabenazine) for the treatment of chorea...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug 11, 2008 - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Viread (tenofovir disoproxil fumarate) for the treatment of chronic...
First New IV Antihypertensive Treatment Approved in Ten Years
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company announced today that the U.S. Food and Drug Administration (FDA) has approved the intravenous (IV) therapy Cleviprex (clevidipine...
Approvals consistent with current US treatment guidelines to start appropriate patients on combination therapies
EAST HANOVER, N.J., August 04, 2008 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination...
CEDAR KNolls, NJ, Aug. 1, 2008-EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today announced that it received FDA approval for Cardene I.V. (nicardipine...
New Drug Applications
VANCOUVER and DEERFIELD, IL, August 11, 2008 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that they have received an action letter dated August 8, 2008 from the...
BRIDGEWATER, N.J., August 08, 2008 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that U.S. Food and Drug Administration (FDA) has assigned priority review status for its New Drug Application (NDA) for Multaq (dronedarone). The priority...
HORSHAM, Pa., August 08, 2008 /PRNewswire/ -- Centocor, Inc., today announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for the Biologic License Application for ustekinumab, a subcutaneous biologic therapy, by...
EXTON, Pa.--(BUSINESS WIRE)--Jul 30, 2008 - Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OT-730, an oculoselective beta-blocker, as a...
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Aug 7, 2008 - GTC Biotherapeutics, Inc. has completed its submission of the final portion of the Biologics License Application, or BLA, for ATryn in the United States. The final portion of the BLA submission...
Clinical Trials
WORCESTER, Mass.--(BUSINESS WIRE)--Aug 19, 2008 - Advanced Cell Technology, Inc. ("ACT") (OTC: ACTC.PK) reported that it is feasible to differentiate and mature human embryonic stem cells (hESCs) into functional oxygen-carrying red blood cells...
AZUSA, Calif.--(BUSINESS WIRE)--Aug 19, 2008 - Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today unveiled a new theory regarding a potential mechanism of action, which could...
BETHESDA, Md., Aug. 19, 2008--The majority of deaths during the influenza pandemic of 1918-1919 were not caused by the influenza virus acting alone, report researchers from the National Institute of Allergy and Infectious Diseases (NIAID),...
LANSDALE, Pa.--(BUSINESS WIRE)--Aug 19, 2008 - Hayes, Inc., an industry leader in providing independent, unbiased analyses of healthcare technologies, today announced that it has completed an exhaustive study of a wide range of medications to treat...
Results of Phase II and III trials add to growing bank of clinical evidence regarding prolonged release oxycodone / naloxone
Cambridge, UK, August 19, 2008- Prolonged release oxycodone / naloxone is as effective as oxycodone alone in providing...
More News Resources
Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals
